GlassScriptPhysician profile
Gregory Dougan
NPI 1568973717
$5,517.03
in general payments reported to CMS, 2019-2025
23 companies · $1,500 in 2025
The $1,500 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $756 · 2022: $891 · 2023: $1,056 · 2024: $1,313 · 2025: $1,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,623 · Education: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,623.25 |
| Education | $245.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,130.46 | 2021-2025 | |
| Abbvie INC. | $1,100.86 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $877.54 | 2021-2025 | Absorica Ld, Winlevi, Ilumya |
| Janssen Biotech, INC. | $543.45 | 2021-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $247.24 | 2023-2025 | Sotyktu |
| Ucb, INC. | $184.79 | 2021-2025 | Bimzelx |
| Organogenesis INC. | $173.49 | 2021-2025 | Affinity, Novachor |
| Regeneron Healthcare Solutions, INC. | $172.61 | 2021-2025 | Dupixent, Libtayo |
| Pfizer INC. | $137.77 | 2021-2025 | |
| Leo Pharma INC. | $136.28 | 2022-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $125.90 | 2021-2025 | Nemluvio |
| Incyte Corporation | $108.57 | 2022-2025 | Opzelura |
| Genzyme Corporation | $91.98 | 2022-2024 | |
| Biofrontera INC. | $89.97 | 2021-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Lilly USA, LLC | $78.61 | 2021-2024 | Ebglyss, Taltz |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $62.45 | 2021-2024 | Erivedge, Xolair |
| Botanix Sb INC | $53.81 | 2025 | Sofdra |
| Convatec INC. | $51.19 | 2023-2025 | |
| Strata Skin Sciences, INC. | $48.81 | 2024-2025 | Xtrac |
| Amgen INC. | $39.55 | 2023-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $33.67 | 2023 | Vtama |
| Vyne Pharmaceuticals INC. | $14.47 | 2021 | |
| Janssen Scientific Affairs, LLC | $13.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Dougan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.